Neha Shrestha
Medical · Annapolis, MDNPI 1285252015
Payments from drug & device makers
Across 166 payments — averaging $19.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$613
- AbbVie$471
- Novo Nordisk$276
- AstraZeneca$266
- Amgen$238
- Pfizer$184
- plus $1K from 17 others
What the payments were for
- Food & beverage$3,224100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 34 | $613 |
| AbbVie | 23 | $471 |
| Novo Nordisk | 14 | $276 |
| AstraZeneca | 14 | $266 |
| Amgen(2 entities) | 11 | $238 |
| Pfizer | 9 | $184 |
| Bayer | 9 | $175 |
| GSK | 8 | $145 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $137 |
| Merck | 7 | $123 |
| Lundbeck LLC | 4 | $87 |
| Idorsia Pharmaceuticals US Inc | 3 | $68 |
| Amarin Pharma, Inc. | 3 | $65 |
| Exact Sciences | 3 | $61 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $52 |
| Boehringer Ingelheim | 3 | $52 |
| Seqirus USA Inc | 3 | $51 |
| Neurocrine Biosciences, Inc. | 2 | $46 |
| Kowa Pharmaceuticals America, Inc. | 3 | $44 |
| Corcept Therapeutics | 1 | $24 |
| Acerus Pharmaceuticals Corporation | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Nevro Corp. | 1 | $14 |
How this compares
$3,224 in reported general payments places this provider in the 80th percentile of 543 medical providers in Maryland.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 17 | $23,196 |
| RybelsusSemaglutide | 11 | $15,147 |
| Rosuvastatin Calcium | 55 | $2,023 |
| Atorvastatin Calcium | 92 | $1,600 |
| Losartan Potassium | 47 | $841 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 16 | $837 |
| Metoprolol Succinate | 29 | $661 |
| Olmesartan Medoxomil | 27 | $609 |
| Amlodipine Besylate | 67 | $562 |
| Levothyroxine Sodium | 44 | $466 |
| Tamsulosin Hcl | 20 | $321 |
| Lisinopril | 34 | $263 |
| Metformin Hcl | 28 | $240 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 13 | $234 |
| Glimepiride | 16 | $207 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $52 | $23,19617 claims |
| Novo NordiskRybelsus | $276 | $15,14711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 543 medical providers in Maryland.
Other medical in Annapolis
- Karen ScottAnnapolis$49K
- Mary HolthausAnnapolis$11K
- Molly WarnockAnnapolis$8K
- Victoria TrottStevensville$94K
- Sarah SagorskyBaltimore$68K
- Emily GrisnikLeonardtown$62K
- Jennifer HamiltonBel Air$52K
- Kristina TrunnellFrederick$51K
- Nicholas WunderAberdeen$40K
- Sarah JamiesonFrederick$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.